Skip to content

Senate Confirmation Hearing for FDA Commissioner Nominee Dr. Scott Gottlieb Begins Today 10am ET

Senate Confirmation Hearing for FDA Commissioner Nominee Dr. Scott Gottlieb Begins Today 10am ET

Today, at 10am ET, Dr. Scott Gottlieb, the President’s nominee for FDA Commissioner, will appear before the Senate Health, Education, Labor and Pensions (HELP) Committee for his confirmation hearing.


  • We will be live-tweeting the hearing: Follow us on Twitter for the latest
  • Senate HELP will also be broadcasting the hearing via webcast

The Advocacy Community Supports Dr. Gottlieb

Included below is a community sign-on letter from more than 20 organizations representing millions of patients, advocates, caregivers, and health care providers supporting the swift confirmation of Dr. Scott Gottlieb as the next Commissioner of the FDA.


April 4, 2017

Dear Majority Leader McConnell, Democratic Leader Schumer, Chairman Alexander, and Ranking Member Murray:

The undersigned organizations, representing millions of patients, advocates, caregivers, and health care providers would like to reaffirm our support for President Trump’s nomination of Dr. Scott Gottlieb as Commissioner of the Food and Drug Administration (FDA). We ask that Senators in the Republican and Democratic caucuses, and the Senate HELP committee, vote to confirm Dr. Gottlieb.

The United States is at a pivotal moment in terms of public health. The FDA and patients need the leadership and experience that Dr. Gottlieb will bring as soon as possible.

Dr. Scott Gottlieb is well qualified and has received broad-based support. Equally important, as a physician who has treated patients, he knows the value of having the best available treatments based on the best science.  As a survivor himself, he knows what it’s like to fight cancer and understands the challenges that patients face every day.
Currently a resident fellow at the American Enterprise Institute focusing on the FDA and CMS, Dr. Gottlieb is also a member of the Federal Health IT Policy Committee. His previous experience includes public service from 2005 to 2007, as FDA deputy commissioner under President George W. Bush.

Dr. Gottlieb has not only the experience that will be critical to expand upon the agency’s important work, but also firsthand expertise as a physician who has treated patients, understanding the breadth of work that needs to be achieved on their behalf.

Dr. Gottlieb’s strong scientific base and in-depth knowledge of key regulatory processes will be key to his success in this position. Due to his knowledge and experience, Dr. Gottlieb is the right person to ensure the FDA keeps pace with science and innovation without sacrificing the safety and efficacy gold standard established by the agency.

Additionally, we know that Dr. Gottlieb can maximize value for patients through the FDA. Congress must ensure that FDA continues its important mission to provide patients with safe and effective treatments. We ask the Senate to do what is right for patients and immediately confirm Dr. Scott Gottlieb as FDA commissioner.


Alliance for Aging Research
American Association for Cancer Research
Association of American Cancer Institutes (AACI)
CEO Roundtable on Cancer
Coalition of Cancer Cooperative Groups
FasterCures, a center for the Milken Institute
Friedreich’s Ataxia Research Alliance (FARA)
Friends of Cancer Research
Global Healthy Living Foundation
Grandparents in Action
Lung Cancer Alliance
Lupus and Allied Diseases Association, Inc.
Men’s Health Network
National Coalition for Cancer Research (NCCR)
National Health Council
National Infusion Center Association (NICA)
National Kidney Foundation
National Patient Advocate Foundation (NPAF)
The Nicholas Conor Institute
Prevent Cancer Foundation
Swifty Foundation

To view the sign on letter with more than 20 organizations, Click HERE.

About Friends of Cancer Research
Friends of Cancer Research (Friends) drives collaboration among partners from every healthcare sector to power advances in science, policy and regulation that speed lifesaving treatments to patients. For more information, please visit